IPSC
NASDAQCentury Therapeutics Inc.
Price$1.42-0.04 (-2.74%)
01:30 PM07:00 PM
News · 26 weeks49-70%
2026-04-192026-10-11
Mix1890d
- Insider10(56%)
- SEC Filings4(22%)
- Other3(17%)
- Leadership1(6%)
Latest news
25 items- PRCentury Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonPHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. If you are interested in a 1x1 meeting with the Century Therapeutics team during the conference, please reach out to your respective Jefferies representative. About Century Therapeutics Century Therapeutics (NASDAQ:IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iP
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- PRCentury Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027 PHILADELPHIA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (("Century", NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation of nonclinical data for CNTY-813, Century's iPSC-derived islet replacement therapy engineere
- INSIDEROfficer Russotti Gregory sold $4,993 worth of shares (2,587 units at $1.93), decreasing direct ownership by 0.51% to 509,198 units (SEC Form 4) to satisfy tax liability4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $3,200 worth of shares (1,658 units at $1.93), decreasing direct ownership by 0.33% to 502,907 units (SEC Form 4) to satisfy withholding obligation4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 13,850 shares, decreasing direct ownership by 0.38% to 3,633,839 units (SEC Form 4) (withholding tax)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Truitt Joseph4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 3 filed by new insider Truitt Joseph3 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 463 shares, decreasing direct ownership by 0.01% to 3,633,839 units (SEC Form 4) to satisfy tax liability4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $521 worth of shares (254 units at $2.05), decreasing direct ownership by 0.05% to 504,565 units (SEC Form 4) to cover withholding tax4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDEROfficer Russotti Gregory sold $1,095 worth of shares (534 units at $2.05), decreasing direct ownership by 0.10% to 511,785 units (SEC Form 4) (tax withholding)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- PRCentury Therapeutics Appoints Joseph Truitt to Board of DirectorsPHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ:LRMR) and a member of the Board of Directors of Code Biotherapeutic
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 31,172 shares, decreasing direct ownership by 0.85% to 3,634,302 units (SEC Form 4) to satisfy withholding obligation4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- SECSEC Form 10-Q filed by Century Therapeutics Inc.10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
- PRCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesCompleted pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1DUpcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D® Clinical & Research Congress 2026 highlighting CNTY-813Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion™ 5.0 into the clinic this yearCa
- INSIDERSVP Finance & Operations Carr Douglas sold $544 worth of shares (275 units at $1.98), decreasing direct ownership by 0.05% to 504,819 units (SEC Form 4) (withholding obligation)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- PRCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, ItalyBreakthrough T1D® Clinical & Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania Both presentations will highlight CNTY-813,
- SECCentury Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Century Therapeutics, Inc. (0001850119) (Filer)
- INSIDEROfficer Russotti Gregory sold $5,767 worth of shares (2,584 units at $2.23), decreasing direct ownership by 0.50% to 512,319 units (SEC Form 4) (for tax liability)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSVP Finance & Operations Carr Douglas sold $3,692 worth of shares (1,654 units at $2.23), decreasing direct ownership by 0.33% to 505,094 units (SEC Form 4) (tax liability)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERPresident and CEO Pfeiffenberger Brent covered exercise/tax liability with 13,849 shares, decreasing direct ownership by 0.38% to 3,665,474 units (SEC Form 4) (withholding tax)4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERChief Scientific Officer Cowan Chad covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.03% to 1,175,322 units (SEC Form 4) to satisfy withholding tax4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- INSIDERSEC Form 4 filed by Director Riva Alessandro4 - Century Therapeutics, Inc. (0001850119) (Issuer)
IPSC FAQ
7 questionsWhat does Century Therapeutics Inc. do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and...Where does IPSC stock trade?
Century Therapeutics Inc. (IPSC) is listed on NASDAQ.What sector and industry is IPSC in?
Century Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Century Therapeutics Inc. go public?
Century Therapeutics Inc. (IPSC) completed its IPO in 2021.What are analysts saying about IPSC?
Century Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Outperform with a $800.00 price target on 2026-05-27.What companies are similar to IPSC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IPSC side-by-side with any of them on Quantisnow.How can I track IPSC on Quantisnow?
Quantisnow aggregates Century Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IPSC to receive live email and push alerts on every new disclosure.